Orchestra BioMed Holdings (OBIO) Cash from Operations Growth (3y) (2024 - 2026)

Orchestra BioMed Holdings (OBIO) Cash from Operations Growth (3y) (2024 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -5.07%
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn - -
3 Akari Therapeutics 1,045.06 Bn 1,045.06 Bn - -
4 BeOne Medicines 470.64 Bn 465.84 Bn 1.35 Bn 33.08%
5 Vertex Pharmaceuticals 122.91 Bn 115.67 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 70.07 Bn 61.31 Bn 3.31 Bn -7.60%
7 Belite Bio 62.77 Bn 62.77 Bn - -
8 Argenx Se 56.21 Bn 51.02 Bn 1.41 Bn -
9 Revolution Medicines 37.60 Bn 37.60 Bn - -
10 Orchestra BioMed Holdings 240.85 Mn 146.45 Mn 78,000.00 -15.52%

Historic Data

Download Data
DateValue
Mar 31, 2026 -15.52%
Dec 31, 2025 36.21%
Sep 30, 2025 -26.10%
Jun 30, 2025 -24.92%
Mar 31, 2025 -46.14%
Dec 31, 2024 -677.22%
Sep 30, 2024 -374.78%
Jun 30, 2024 -538.85%
Mar 31, 2024 -455.81%